Cochlear Implants: Candidacy, Telemetry, MAPping Parameters & ABI Systems

Cochlear Implants & Auditory Brainstem Implants

Cochlear implants (CIs) represent one of the most successful neural prostheses in modern medicine, converting acoustic signals into patterned electrical current pulses that directly stimulate spiral ganglion auditory nerve fibers in the modiolus. When bilateral cochlear or neural devastation precludes peripheral stimulation, Auditory Brainstem Implants (ABIs) provide central electrical stimulation at the brainstem. Mastering candidacy criteria, surgical principles, electroacoustic preservation, and objective telemetry is fundamental for the clinical audiologist.

---

CI System Architecture & Surgical Anatomy

A cochlear implant system consists of two primary hardware sections:

1. External Equipment:
   • Microphones: Dual directional beamforming microphones that capture ambient acoustic sound and optimize speech-to-noise ratios.
   • Speech Processor: A digital signal processor that digitizes acoustic waveforms, divides them into discrete band-pass frequency channels, extracts temporal amplitude envelopes, and translates them into high-speed electrical pulse trains.
   • Transmitting Coil: Contains an internal magnet that couples across the intact scalp to the internal receiver, transmitting digital data and power via a high-frequency transcutaneous radiofrequency (RF) link.
   • Power Source: Rechargeable lithium-ion or high-capacity disposable zinc-air battery cells.
2. Internal Equipment:
   • Receiver-Stimulator: Encased in a hermetically sealed, medical-grade titanium and ceramic housing recessed into a surgically created bone bed in the parietal-temporal squama. It contains decoding microchips, a retention magnet, an extra-cochlear ground electrode, and current generators.
   • Electrode Array: A flexible silastic carrier containing 12 to 24 platinum-iridium electrode contacts inserted through a mastoidectomy and facial recess approach (posterior tympanotomy) into the scala tympani.

Surgical Insertion & Cochlear Tonotopicity

• Scala Tympani Preference: The electrode array is surgically inserted into the scala tympani via the round window membrane or an anteroinferior cochleostomy. Insertion into the scala tympani is critical: it places electrodes closest to the primary auditory neurons (spiral ganglion cells) situated in the modiolus, while avoiding rupture of the basilar membrane or osseous spiral lamina. Translocation of the array into the scala vestibuli damages residual hair cells, causes intracochlear fibrosis, and markedly reduces speech outcomes.
• Tonotopic Organization: Human cochlear frequency mapping is strictly tonotopic. The basal turn represents high frequencies ($2000-8000\,\text{Hz}$), the middle turn represents intermediate frequencies ($800-2000\,\text{Hz}$), and the apical turn represents low frequencies ($100-800\,\text{Hz}$). CI sound processors assign high-pass filtered channels to basal electrodes and low-pass filtered channels to apical electrodes.

---

FDA & CMS Candidacy Criteria Across the Lifespan

Cochlear implant candidacy has evolved from post-lingual bilateral total deafness to include significant residual hearing, pediatric infants, and asymmetric hearing configurations.

1. Adults ($\ge 18$ Years of Age)

• Audiometric Thresholds: Bilateral moderate-to-profound sensorineural hearing loss in the low frequencies, sloping to severe-to-profound sensorineural loss in the mid-to-high frequencies ($>1000\,\text{Hz}$).
• FDA Speech Recognition Benchmarks: Evaluated under best-aided condition (using modern, properly fitted bilateral hearing aids verified via probe-microphone measurements):
  • Open-set sentence recognition (e.g., AzBio sentences in quiet or $+10$ or $+5\,\text{dB}$ SNR, or HINT sentences) $\le 50\%$ in the ear to be implanted.
  • Open-set sentence recognition $\le 60\%$ in the contralateral ear or in the binaural aided condition.
• Medicare (CMS) Coverage Criteria (Exam Trap: Know the 2022 Update):
  • Under National Coverage Determination 50.3, effective September 26, 2022, Medicare covers cochlear implantation for bilateral moderate-to-profound sensorineural loss with limited benefit from amplification, defined as $\le 60\%$ correct in the best-aided condition on recorded open-set sentence tests.
  • The older rule ($\le 40\%$, with $41\%$ to $60\%$ covered only inside approved clinical studies) no longer applies; the clinical-trial requirement was removed.

2. Children Aged 2 to 17 Years

• Audiometric Thresholds: Bilateral severe-to-profound sensorineural hearing loss (pure-tone average $\ge 70\,\text{dB HL}$ at $500, 1000, 2000\,\text{Hz}$).
• Speech Recognition Benchmarks: Open-set word recognition scores $\le 30-32\%$ on recorded phonetically balanced materials:
  • Multisyllabic Lexical Neighborhood Test (MLNT) or Lexical Neighborhood Test (LNT) for younger children.
  • Phonetically Balanced Kindergarten (PBK) word lists for older pediatric candidates.
• Aided Trial: Demonstration of limited functional auditory progress after a 3- to 6-month trial with optimized bilateral acoustic amplification and intensive auditory-verbal therapy.

3. Infants Aged 9 to 24 Months

• Audiometric Thresholds: Bilateral profound sensorineural hearing loss (pure-tone and ABR thresholds $\ge 90\,\text{dB HL}$). Confirmed via diagnostic auditory brainstem response (ABR), distortion product otoacoustic emissions (DPOAE), and behavioral observation audiometry (BOA).
• Auditory Progress Benchmarks: Failure to achieve developmentally appropriate auditory milestones as documented on validated parent questionnaires such as the IT-MAIS (Infant-Toddler Meaningful Auditory Integration Scale) or LittlEARS.
• Hearing Aid Trial: Minimum 3- to 6-month trial with high-power hearing aids paired with an auditory habilitation program.
• Urgent Exception (Post-Meningitic Ossification): In cases of bacterial meningitis (e.g., Streptococcus pneumoniae), rapid suppurative labyrinthitis can lead to fibroblastic proliferation and labyrinthitis ossificans—new bone formation that completely obliterates the patent scala tympani within weeks. In post-meningitis patients with profound hearing loss and early signs of cochlear obliteration on high-resolution T2-weighted MRI, the hearing aid trial is waived, and emergency cochlear implantation is performed immediately before the cochlear lumen is permanently ossified.

---

Electroacoustic Stimulation (EAS) & Hybrid Implantation

Electroacoustic Stimulation (EAS), commonly referred to as Hybrid Cochlear Implantation, is designed for patients with substantial usable low-frequency acoustic hearing combined with profound high-frequency sensory impairment.

Audiometric Configuration & Mechanism

• Preoperative Audiogram: Normal-to-moderate sensorineural hearing loss at low frequencies (thresholds $\le 60\,\text{dB HL}$ at $125, 250, 500\,\text{Hz}$), dropping precipitously to severe-to-profound loss at $1000\,\text{Hz}$ and above.
• Hardware Configuration: A hybrid processor combines an acoustic earphone (receiver in the canal or custom earmold) that amplifies low frequencies acoustically ($<500-1000\,\text{Hz}$) with an electrical speech processor driving an intracochlear array for mid-to-high frequencies ($>1000\,\text{Hz}$).
• Atraumatic Surgical Technique: Utilizes a thin, highly flexible, shorter electrode array ($16-24\,\text{mm}$) inserted atraumatically through the round window without suctioning perilymph. This preserves delicate apical sensory hair cells, supporting structures, and the endocochlear potential in the apical turns of the scala tympani.
• Clinical Benefits: Preserving apical acoustic hearing provides pristine fine-structure timing cues, precise fundamental frequency ($F_0$) pitch perception, and access to low-frequency interaural time differences (ITD). Consequently, EAS recipients demonstrate dramatically superior speech recognition in background noise, voice pitch discrimination, and musical melody recognition compared to conventional full-band electrical stimulation.

---

CI Programming & MAPping Parameters

Audiological MAPping configures the electrical stimulation parameters delivered to each individual electrode contact to match the user's perceptual dynamic range.

Primary MAPping Parameters

1. Threshold Levels (T-Levels):
   • Definition: The lowest amount of electrical current that produces a barely audible auditory sensation (100% detection threshold).
   • Clinical Measurement: Established behaviorally using modified counting procedures in adults, or visual reinforcement audiometry (VRA) / conditioned play audiometry (CPA) in children.
   • Clinical Impact: If T-levels are set too low, soft speech sounds become inaudible; if set too high, the patient hears a persistent, annoying background hum or buzz, and the usable dynamic range is compressed.
2. Comfort Levels (C-Levels / M-Levels / MCL):
   • Nomenclature: Termed C-level (Cochlear, Oticon Medical), M-level (Advanced Bionics), or MCL (MED-EL).
   • Definition: The maximum electrical stimulation level that sounds comfortably loud without causing discomfort, pain, or non-auditory sensations.
   • Clinical Measurement: Swept across electrodes to balance loudness across all channels.
   • Clinical Impact: Setting comfort levels too high causes sound distortion, severe loudness intolerance, aversion, and facial nerve stimulation. Setting comfort levels too low restricts the dynamic range, resulting in a thin, hollow sound quality and poor speech recognition.
3. Electrical Dynamic Range (EDR):
   • The mathematical difference between the T-level and the C/M-level on a given channel, expressed in manufacturer-specific current units (charge units, clinical units, or microcoulombs).
4. Stimulation Rate:
   • Expressed in pulses per second (pps) per channel. Modern CIS (Continuous Interleaved Sampling) and ACE (Advanced Combination Encoders) strategies employ rates from 250 to over 1200 pps/channel. Higher rates improve fine temporal envelope cues but increase neural refractory fatigue and channel interaction.
5. Pulse Width:
   • The duration of each phase of the biphasic cathodic-anodic current pulse, measured in microseconds ($\mu\text{s}$). Total electrical charge delivered per phase is $Q = I \times t$ (current amplitude $\times$ pulse width). When an electrode requires more charge to achieve comfort but reaches the processor's maximum battery voltage limit (compliance limit), the audiologist increases the pulse width, allowing adequate charge delivery at lower current amplitudes.

---

Objective Electrophysiology & Telemetry

Objective telemetry tools are essential for intraoperative monitoring, pediatric fitting, and hardware troubleshooting.

1. Electrode Impedance Telemetry

• Biophysical Principle: Measures the opposition to electrical current flow through each electrode contact into the surrounding perilymph and tissue ($Z = V / I$).
• Normal Range: Typically $1.0\,\text{k}\Omega$ to $15.0\,\text{k}\Omega$.
• Open Circuit ($>20-30\,\text{k}\Omega$): Abnormally high impedance indicating a physical fracture in the electrode lead wire, a detached electrode contact, or an air bubble surrounding the contact. Open-circuit electrodes cannot deliver current and must be deactivated in the MAP.
• Short Circuit ($<1.0\,\text{k}\Omega$): Abnormally low impedance indicating an electrical bridge between two adjacent contacts caused by direct physical contact or fluid intrusion into the array carrier. Short-circuited electrodes distort current spread and must be deactivated.

2. Neural Response Telemetry (NRT / NRI / ART)

• Biophysical Principle: Measures the Electrically Evoked Compound Action Potential (ECAP) of the auditory nerve. The system delivers a suprathreshold electrical biphasic pulse on one electrode and uses an adjacent contact to record the synchronous firing of spiral ganglion auditory nerve fibers.
• Waveform Morphology: Features a prominent negative peak (N1) occurring at $0.2-0.4\,\text{ms}$ post-stimulus, followed by a positive peak (P1) at $0.6-0.8\,\text{ms}$.
• Clinical Application: ECAP thresholds correlate with behavioral T- and C-levels, providing objective physiological starting levels for programming infants, non-verbal children, and difficult-to-test populations.

3. Electrically Evoked Stapedial Reflex Threshold (ESRT)

• Objective measurement of the acoustic reflex threshold elicited by CI electrical stimulation, monitored visually under an operating microscope during surgery or via an acoustic immittance bridge in the contralateral ear.
• ESRTs correlate strongly ($r \approx 0.85-0.90$) with behavioral upper comfort levels (C/M-levels), preventing overstimulation in pediatric fittings.

---

Auditory Brainstem Implants (ABI)

When the auditory nerve (cranial nerve VIII) is anatomically interrupted, absent, or non-functional, a cochlear implant cannot transfer electrical signals to the brain. In these patients, the Auditory Brainstem Implant (ABI) provides a direct central auditory neural prosthesis.

Surgical Anatomy & Placement

• Target Structure: The multi-electrode paddle array (containing 12 to 21 platinum disc contacts embedded in a silicone/Dacron mesh) is surgically placed into the lateral recess of the fourth ventricle (via the foramen of Luschka) to rest directly against the surface of the cochlear nucleus (dorsal and ventral cochlear nuclei) on the brainstem pons.
• Surgical Approach: Typically performed via a retrosigmoid or translabyrinthine craniotomy by a skull-base neurotological/neurosurgical team.

Clinical Indications

1. Neurofibromatosis Type 2 (NF2): The primary FDA-cleared indication. Patients develop bilateral vestibular schwannomas. Surgical resection of these tumors frequently requires complete transection or devascularization of the cochlear nerve bilaterally.
2. Non-NF2 Indications (Pediatric & Investigational): Complete bilateral cochlear nerve aplasia or hypoplasia, bilateral auditory nerve avulsion from severe temporal bone fractures, or complete labyrinthine ossification post-meningitis where a CI electrode array cannot be inserted.

Clinical Outcomes & Counseling Realities

• Auditory Performance: Unlike cochlear implants, where over $80\%$ of adult recipients achieve open-set speech understanding, ABI outcomes in adult NF2 patients are modest. The primary benefits are sound awareness, environmental noise identification, speech cadence and rhythm discrimination, and substantial enhancement of visual lipreading (speechreading).
• Open-Set Speech: Only a small minority ($5-15\%$) of adult NF2 ABI recipients achieve open-set sentence understanding without lipreading, primarily due to tumor-induced brainstem damage, surgical trauma, and the lack of discrete tonotopic organization at the brainstem surface.
• Non-Auditory Side Effects: Because the cochlear nucleus is situated adjacent to other cranial nerve nuclei and tracts in the brainstem, electrical stimulation can spread, causing non-auditory sensations: facial muscle twitching (cranial nerve VII), tongue paresthesia (cranial nerve XII), throat tickling or coughing (cranial nerves IX and X), or motor tingling in the extremities (spinothalamic/pyramidal tracts). Any electrode contact eliciting non-auditory side effects must be deactivated during programming.